City Therapeutics, Inc. Common Stock
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Latest news
All CTY news ›U.S. IPO Weekly Recap: Biotechs City Therapeutics And Iambic Headline The Week's Pricings
Seeking Alpha - Three IPOs and two SPACs priced this week, and two SPACs submitted filings. - No IPOs are currently scheduled for the week ahead as the year’s next mega IPO potentially comes into view. - Street research is expected to for…
City Therapeutics Announces Pricing of Upsized Initial Public Offering
CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- City Therapeutics, Inc. (Nasdaq: CTY) ('City” or 'City Therapeutics”), a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics, today…
City Therapeutics Announces $99.5 Million Series B Financing to Advance Next-Generation RNAi Therapeutics
Viking Global Investors and Sofinnova Investments join a strong syndicate of existing investors including ARCH Venture Partners, Fidelity Management & Research Company and Invus Proceeds to accelerate the company’s RNAi engineering…
City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to…
City Therapeutics Prices Upsized IPO Of 11.1 Million Shares Of Its Common Stock At $18 Per Share
TradingView City Therapeutics Prices Upsized IPO Of 11.1 Million Shares Of Its Common Stock At $18 Per Share
City Therapeutics, Inc. has completed an IPO in the amount of $199.999998 million.
marketscreener.com City Therapeutics, Inc. has completed an IPO in the amount of $199.999998 million. Published on 10/15/2026 at 11:20 pm EDT Latest news about City Therapeutics, Inc. Chart City Therapeutics, Inc. Income Statement and…
City Therapeutics, Inc.: Relative Strength Chart - Stock Nasdaq
Compare City Therapeutics, Inc. with the company of your choice via a Relative Strength chart. Real-time CTY price, Nasdaq stock exchange Relative Strength Chart City Therapeutics, Inc. All financial news and data tailored to specific…
City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
City Therapeutics, the RNA interference biotech developing therapies for thromboembolic diseases, has pulled off an upsized IPO, raising $200 million that will be split across its pipeline. The company will begin trading on the Nasdaq…
RNAi biotech City hauls in $200m in upsized IPO
John Maraganore, co-founder and executive chair of City Therapeutics. City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference (RNAi) therapies headed by a novel anticoagulant drug. The listing was…
Next-gen RNAi drugmaker City prices $200M IPO
The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver. City Therapeutics, a buzzy biotechnology startup working on new types…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
tradingview.com20
-
investors.citytx.com2
-
marketscreener.com2
-
seekingalpha.com2
-
allsci.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 48 articles, not a forecast.